Canaccord lowered the firm’s price target on Cybin (CYBN) to $86 from $96 and keeps a Buy rating on the shares. The firm said they reported results and he key update was that the company has started its PARADIGM Phase 3 program for CYB003 (deuterated psilocybin analog) as an adjunct treatment for major depressive disorder (MDD).
Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN: